Guest guest Posted February 1, 2011 Report Share Posted February 1, 2011 February 1, 2011 HCV » February Newsletter » HCV Fact Sheets » Educational Materials » HCSP Streaming Videos Greetings: This week's postings include: February 2011 HCV Advocate newsletter that includes: An article about the priority review given for boceprevir and telaprevir in the United States and the European Union. In addition, telaprevir has been grant priority review in Canada. "News Briefs" contains an overview of important news stories, including the first real collaboration between HCV pharmaceuticals, new guidelines on acetaminophen dosage, pilot programs for the HCV aged-based testing initiatives, and the use of medicines to prevent the recurrence of hepatitis C after liver transplantation. "HCV Snapshots" for February are devoted to research on the association between HCV, stroke and heart disease, "HealthWise"'s topic this month is a further exploration of the heart and HCV February HBV Journal Review that includes: A push to increase the diagnosis of liver cancer A new and more accurate liver cancer marker Early identification of liver cancer = longer survival Women with HBV and Non-Hodgkin Lymphoma cancer First-line of treatment - pegylated interferon or HBV antivirals? Liver disease and risk of stroke ...and many more articles Don't forget to check out our blog for more about the most recent news stories. Sincerely,Alan Join me on Twitter - . Alan Franciscus Executive Director, Hepatitis C Support Project Editor-in-Chief, HCV Advocate www.hcvadvocate.org Editor-in-Chief, HBV Advocate www.hbvadvocate.org . **Questions and Comments: Questions and/or comments can be directed to alanfranciscus@... .. HBV » HBV Journal Review » HBV Factsheets » HBV & HCV Advocate Hepatitis Blog » Stay connected with all the late-breaking news on hepatitis B-Join us on Twitter Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.